ID: h-527d32c9
Hypothesis
GrimAge Acceleration as a Cell-Type-Resolved CSF Biomarker Panel for Early AD Stratification
Concise Statement: GrimAge-derived epigenetic age acceleration, when deconvoluted for neuronal vs.
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Concise Statement: GrimAge-derived epigenetic age acceleration, when deconvoluted for neuronal vs. glial cell-type proportions in CSF-derived cell-free DNA, will outperform single-tissue blood-based clocks in distinguishing early Alzheimer's disease from MCI and healthy aging with >85% sensitivity and specificity.
Mechanistic Rationale:
GrimAge incorporates plasma protein surrogates (including GDF-15, PAI-1, and smoking-related methylation signals) that are biologically proximal to neuroinflammatory and vascular aging cascades relevant to AD. CSF cell-free DNA carries fragments shed from neurons, astrocytes, and microglia that are differentially methylated during AD pathogenesis. By integrating GrimAge acceleration with deconvolution algorithms that parse cell-type contributions, the composite signal would reflect both the pace of brain-specific aging and the cellular source of that acceleration — a dimension unavailable to blood-only clocks.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["GrimAge Acceleration<br/>Epigenetic Age Signal"]
B["CSF Cell-Free DNA<br/>Neuronal Glial Fragments"]
C["Cell-Type Deconvolution<br/>Proportions"]
D["Neuronal Proportion<br/>vs Glial Proportion"]
E["GrimAge Plus<br/>Cell-Type Composite"]
F["Early AD Stratification<br/>vs MCI vs Healthy"]
G[">85% Sensitivity<br/>Specificity"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
CSF markers of vascular injury correlate with tau and cognitive decline in early Alzheimer's disease.
Supports
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
Supports
Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.
Supports
Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study.
Contradicts
GrimAge shows limited accuracy for predicting cardiovascular events in diverse populations independent of genetic factors.
Abstract
Studies examining GrimAge's ability to predict mortality independent of genetic influences show mixed results across populations.
Contradicts
GrimAge acceleration is not independently predictive of AD risk after adjusting for standard cardiovascular and metabolic risk factors.
Abstract
Epigenetic age acceleration markers like GrimAge are heavily confounded by comorbidities and lifestyle factors.
📖 Linked Papers (15)Export BibTeX ↗
CSF markers of vascular injury correlate with tau and cognitive decline in early Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association (2025) · PubMed:41319164 ↗
No figures
CSF markers of vascular injury correlate with tau and cognitive decline in early Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association (2025) · PubMed:41319164 ↗
No figures
Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study.
Alzheimer's & dementia : the journal of the Alzheimer's Association (2025) · PubMed:39428831 ↗
No figures
Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study.
Alzheimer's & dementia : the journal of the Alzheimer's Association (2025) · PubMed:39428831 ↗
No figures
Sex Differences in Alzheimer's Disease.
Neurologic clinics (2023) · PubMed:37030962 ↗
No figures
Sex Differences in Alzheimer's Disease.
Neurologic clinics (2023) · PubMed:37030962 ↗
No figures
DNA methylation GrimAge version 2.
Aging (Albany NY) (2022) · PubMed:36516495 ↗
No figures
Epigenetic clock: A promising biomarker and practical tool in aging.
Ageing Res Rev (2022) · PubMed:36206857 ↗
No figures
Epigenetic GrimAge acceleration and cognitive impairment in bipolar disorder.
Eur Neuropsychopharmacol (2022) · PubMed:35810614 ↗
No figures
No figures
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
Brain : a journal of neurology (2021) · PubMed:33283854 ↗
No figures
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
Brain : a journal of neurology (2021) · PubMed:33283854 ↗
No figures
🏥 Translation
🧬 3D Protein Structure — CSF
No curated PDB or AlphaFold mapping for CSF yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CSF, DNA, MCI, GDF, PAI.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1602
Events (7d)
1
Price History
▲7.1%💾 Resource Usage
LLM Tokens
424,159
$1.5538
API Calls
36
Total Cost
$1.5538
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF GrimAge acceleration is a cell-type-resolved CSF biomarker for early AD, THEN CSF immune-cell deconvolution plus GrimAge residuals will classify MCI amyloid-positive participants versus amyloid-neg | Cell-type-adjusted CSF methylation GrimAge residual model reaches AUC >=0.75 for amyloid-positive MCI status. | — no observation — | pending | 0.57 |
| IF GDF/PAI-linked GrimAge components reflect early AD biology, THEN their CSF methylation module scores will predict 12-month p-tau181 increase of >=15% among MCI participants. | Top-quartile CSF GrimAge component score predicts >=15% higher annual p-tau181 rise than bottom quartile. | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 57%
IF GrimAge acceleration is a cell-type-resolved CSF biomarker for early AD, THEN CSF immune-cell deconvolution plus GrimAge residuals will classify MCI amyloid-positive participants versus amyloid-negative controls with AUC >=0.75 within 18 months.
Predicted outcome: Cell-type-adjusted CSF methylation GrimAge residual model reaches AUC >=0.75 for amyloid-positive MCI status.
Falsification: The model AUC is <0.62 or does not improve by >=0.05 over age, APOE, and total-tau baseline covariates.
pendingconf 55%
IF GDF/PAI-linked GrimAge components reflect early AD biology, THEN their CSF methylation module scores will predict 12-month p-tau181 increase of >=15% among MCI participants.
Predicted outcome: Top-quartile CSF GrimAge component score predicts >=15% higher annual p-tau181 rise than bottom quartile.
Falsification: Top versus bottom quartile p-tau181 change differs by <5% or reverses direction.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.